Evidence map›Paper›PMID 42159963›Full record

ArticleEJNMMI radiopharmacy and chemistry2026

Radiochemistry and comparative in vitro assessment of PSMA-617 labeled with lead-212 (

Abhijit Bera, Graham Ragland, Yuhan Zhang, Patricia G Madel, Jasmine B'Lanton, Atchimnaidu Siriki, Chin-Tu Chen, Russell Z Szmulewitz, Satish K Chitneni

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Abhijit BeraDepartment of Radiology, The University of Chicago, Chicago, IL, USA.
Graham RaglandDepartment of Radiology, The University of Chicago, Chicago, IL, USA.
Yuhan ZhangDepartment of Medicine, The University of Chicago, Chicago, IL, USA.
Patricia G MadelDepartment of Medicine, The University of Chicago, Chicago, IL, USA.
Jasmine B'LantonDepartment of Medicine, The University of Chicago, Chicago, IL, USA.
Atchimnaidu SirikiDepartment of Radiology, The University of Chicago, Chicago, IL, USA.
Chin-Tu ChenDepartment of Radiology, The University of Chicago, Chicago, IL, USA.
Russell Z SzmulewitzDepartment of Medicine, The University of Chicago, Chicago, IL, USA.
Satish K ChitneniDepartment of Radiology, The University of Chicago, Chicago, IL, USA. schitneni@uchicago.edu.ORCID http://orcid.org/0000-0003-1183-2286

Funding

Novartis Institutes for BioMedical Research Novartis Institutes for BioMedical Research
6 · The paper itself

Abstract

backgroundPSMA-targeted radioligand therapy is a promising approach for the treatment of advanced prostate cancer; however, the clinical efficacy of [

resultsThe radioligands were synthesized with an isolated radiochemical yield of > 95% for [

conclusion[

Indexed as

177Lu212Pb225AcProstate cancerPSMA-617Targeted alpha therapy

Identifiers

PMID42159963
PMCPMC13328690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.